Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
J Neuroendocrinol. 2021 Nov;33(11):e13011. doi: 10.1111/jne.13011. Epub 2021 Jul 8.
In the 40 years since vasopressin (AVP) was reported to have a central action with respect to raising blood pressure, the finding has been repeatedly replicated using a variety of complimentary approaches. The role of AVP as a central neurotransmitter involved in control of the cardiovascular system is now textbook material. However, it is evident that brain AVP plays, at best, a minor role in regulation of normal blood pressure. However, it appears to be an important player in a several cardiovascular-associated pathologies, ranging from hypertension to neural changes associated with heart failure. There are many interventions that have been shown to affect neural function, many of which are associated with alterations in behaviour. Possible alterations in neuronal AVP actions relevant to cardiovascular control in the setting of chronic inflammatory disease, early-life stress and inflammation are suggested areas for future research.
自加压素 (AVP) 被报道具有升高血压的中枢作用以来的 40 年中,已经使用各种互补方法反复复制了这一发现。AVP 作为一种参与心血管系统控制的中枢神经递质的作用现在已成为教科书内容。然而,很明显,脑 AVP 在调节正常血压方面最多只起次要作用。然而,它似乎是几种与心血管相关的病理学中的重要参与者,从高血压到与心力衰竭相关的神经变化。已经有许多干预措施被证明可以影响神经功能,其中许多与行为改变有关。在慢性炎症性疾病、生命早期应激和炎症的背景下,神经元 AVP 作用可能发生与心血管控制相关的改变,这是未来研究的建议领域。